NRP2 and glioblastoma: Based on this study, the SEMA3F-mimetic bsAb P1943-Nb2cL shows promise for preclinical mouse models and eventually clinical trials targeting glioblastoma and other cancers that express high levels of NRP2 and PLXNA1.